Brief: BioArctic Partner Submits Leqembi sBLA To FDA
02/04/2024 07:15
April 2 (Reuters) - BioArctic AB BIOAb.ST :
* SAID ON MONDAY THAT CO'S PARTNER EISAI ANNOUNCED IT HAS
SUBMITTED SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) FOR
MONTHLY LECANEMAB-IRMB (U.S. BRAND NAME: LEQEMBI) INTRAVENOUS
MAINTENANCE DOSING TO THE U.S. FDA
Source text for Workspace: urn:newsml:reuters.com:*:nWkr39n7jl
Further company coverage: BIOAb.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on BioArctic AB (publ)
See all newsBrief: BioArctic Gets Leqembi Pen Subcutaneous Formulation Approval In Japan
Brief: BioArctic Says Leqembi Subcutaneous Formulation Approved For Initiation Treatment In China
Brief: BioArctic Says Canada's Drug Agency Issues Final Positive Recommendation Supporting Public Reimbursement Of Leqembi
Sweden's BioArctic Q2 revenue falls despite higher Leqembi royalties
Brief: BioArctic Q2 Net Sales Down At SEK 247.5 Mln